Thomsen–Friedenreich antigen (Galβ1-3GalNAcα1-Ser/Thr) is a disaccharide that serves as a core 1 structure in O-linked glycosylation.[1] First described by Thomsen as a red blood cell's antigen, later research have determined it to be an oncofetal antigen.[2] it is present in the body as a part of membrane transport proteins where it is normally masked from the immune system.[3] It is commonly demasked in cancer cells, with it being expressed in up to 90% of carcinomas, making it a potential target for immunotherapy.[2]

References

  1. Yu, Lu-Gang (2007). "The oncofetal Thomsen–Friedenreich carbohydrate antigen in cancer progression". Glycoconjugate Journal. 24 (8): 411–20. doi:10.1007/s10719-007-9034-3. PMID 17457671. S2CID 9264538.
  2. 1 2 Kurtenkov, Oleg (2020-03-24). "Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential". BioMed Research International. 2020: 1–12. doi:10.1155/2020/9747040. ISSN 2314-6133. PMC 7128052. PMID 32280709.
  3. Karsten, U.; Goletz, S. (July 2015). "What controls the expression of the core-1 (Thomsen—Friedenreich) glycotope on tumor cells?". Biochemistry (Moscow). 80 (7): 801–807. doi:10.1134/S0006297915070019. ISSN 0006-2979. PMID 26541995. S2CID 17278587.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.